Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 10514660
• 负责人: RAPHAEL E. POLLOCK
• 金额: $ 10.75万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-12 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514660
• 关键词: Address; Appalachian Region; Attention; Basic Science; Breast; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Research Project; Cancer Survivorship; Catchment Area; Chemoprevention; Clinical Research; Clinical Trials; Colorectal; Community Networks; Community Outreach; Comprehensive Cancer Center; Descriptor; Doctor of Philosophy; Education and Outreach; Endometrial; Engineering; Etiology; FDA approved; Faculty; Fostering; Funding; Growth; Hematopoietic Neoplasms; Human Papilloma Virus Vaccination; Immunooncology; Intervention; Investments; Journals; Leadership; Lesbian Gay Bisexual Transgender Queer; Longevity; Lung; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Manuscripts; Mission; Molecular Biology; Molecular Carcinogenesis; Morbidity - disease rate; Multicultural Education; Obesity; Ohio; Oncology; Patients; Peer Review; Pharmaceutical Preparations; Policies; Population; Population Research; Population Sciences; Prevention; Prostate; Public Health; Publications; Publishing; Research; Resource Sharing; Resources; Rural; Scanning; Scientist; Screening for cancer; Strategic Planning; Therapeutic Trials; Thyroid Gland; Tobacco use; Training; Translating; Translational Research; Underserved Population; Universities; University resources; Vision; anticancer research; cancer genetics; cancer prevention; cancer research center director; clinical development; community engagement; ethnic minority; innovation; leukemia; member; mortality; next generation; outreach; preclinical development; programs; racial and ethnic; recruit; screening; survivorship; translational genomics; translational therapeutics

PROJECT SUMMARY – OVERALL The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an “exceptional” overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.

项目总结-整体